(Q51541408)

6 April 2018

title

Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. (English)

1 reference

6 April 2018

author

Sylvie Chevret

series ordinal

3

1 reference

6 April 2018

Matthieu Resche-Rigon

object named as

Matthieu Resche-Rigon

series ordinal

2

0 references

author name string

Sarah Zohar

series ordinal

1

1 reference

6 April 2018

publication date

8 August 2011

1 reference

6 April 2018

published in

Clinical Trials

1 reference

6 April 2018

volume

10

1 reference

6 April 2018

issue

3

1 reference

6 April 2018

page(s)

414-421

1 reference

6 April 2018

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Drug development in oncology: classical cytotoxics and molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Tocolytic effects of intravenous nitroglycerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Minimum effective dose of midazolam for sedation of mechanically ventilated neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Dose escalation methods in phase I cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

A comparison of two phase I trial designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Curve-free and model-based continual reassessment method designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Continual reassessment method: a likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

The continual reassessment method in cancer phase I clinical trials: a simulation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Model calibration in the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

The dose of granulocyte-colony-stimulating factor after chemopriming treatment does not influence apheresis yield of progenitor cells: a retrospective study of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774511411593

21 January 2018

Identifiers

DOI

10.1177/1740774511411593

1 reference

6 April 2018

1 reference

6 April 2018